Controlling complement resistance in cancer by using human monoclonal antibodies that neutralize complement-regulatory proteins CD55 and CD59.
about
The dual role of complement in cancer and its implication in anti-tumor therapyNew potential therapeutic approach for the treatment of B-Cell malignancies using chlorambucil/hydroxychloroquine-loaded anti-CD20 nanoparticlesThe good and evil of complement activation in HIV-1 infectionA recombinant adenovirus type 35 fiber knob protein sensitizes lymphoma cells to rituximab therapyComplement anaphylatoxins as immune regulators in cancer.Prevention of arthritis by locally synthesized recombinant antibody neutralizing complement component C5.Rituximab resistance.Generation of 1E8 Single Chain Fv-Fc Construct Against Human CD59.Combined yeast {beta}-glucan and antitumor monoclonal antibody therapy requires C5a-mediated neutrophil chemotaxis via regulation of decay-accelerating factor CD55Human CD59 inhibitor sensitizes rituximab-resistant lymphoma cells to complement-mediated cytolysis.CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment: setting the stage for anti-CD20 directed immunotherapyComplement factor H-derived short consensus repeat 18-20 enhanced complement-dependent cytotoxicity of ofatumumab on chronic lymphocytic leukemia cells.Rapid degradation of the complement regulator, CD59, by a novel inhibitorRituximab: a review of dermatological applications.Complement in cancer and cancer immunotherapy.Protein engineering to target complement evasion in cancer.Regulation of complement and modulation of its activity in monoclonal antibody therapy of cancer.Rituximab: modes of action, remaining dispute and future perspective.CMC-544 (inotuzumab ozogamicin), an anti-CD22 immuno-conjugate of calicheamicin, alters the levels of target molecules of malignant B-cells.Application of a novel inhibitor of human CD59 for the enhancement of complement-dependent cytolysis on cancer cells.rILYd4, a human CD59 inhibitor, enhances complement-dependent cytotoxicity of ofatumumab against rituximab-resistant B-cell lymphoma cells and chronic lymphocytic leukemia.CD52 over-expression affects rituximab-associated complement-mediated cytotoxicity but not antibody-dependent cellular cytotoxicity: preclinical evidence that targeting CD52 with alemtuzumab may reverse acquired resistance to rituximab in non-HodgkiCorrelation between cellular expression of complement regulatory proteins with depletion and repopulation of B-lymphocytes in peripheral blood of patients with rheumatoid arthritis treated with rituximab.Rituximab treatment in patients with active Graves' orbitopathy: effects on proinflammatory and humoral immune reactions.Hepatitis B virus X protein activates CD59 involving DNA binding and let-7i in protection of hepatoma and hepatic cells from complement attack.Red Blood Cells: A Source of Extracellular Vesicles.Bispecific antibodies targeting tumor-associated antigens and neutralizing complement regulators increase the efficacy of antibody-based immunotherapy in mice.Effect of membrane-bound complement regulatory proteins on tumor cell sensitivity to complement-dependent cytolysis triggered by heterologous expression of the α-gal xenoantigen.Complement and cellular cytotoxicity in antibody therapy of cancerComplement as a Biological Tool to Control Tumor Growth
P2860
Q26738682-8394F452-3098-4391-8F22-D6B65750FB08Q27306995-0386BB8C-10F8-4C60-ADC8-0BF9680E5685Q28275986-B5B58F22-08FF-45A1-8B3A-1D82A032F2CBQ30959165-32F7FB2E-2A20-4228-934D-AD1CE1499B04Q34414162-EBF9B6BC-8E5C-4905-999E-501813A203C2Q34625994-F366FEFE-6481-4D92-8C58-75640E70BFE7Q35041270-C98D807E-4B87-4FF3-AF99-6D2FC2B96B01Q35897605-6C48B4DD-190A-47D3-BA50-7ADE7AE43A52Q35914730-044483AA-26BE-4078-8151-A86CC94A66F8Q36754719-6709F5F0-3528-4B09-A94E-808C424D4705Q36969800-53DED190-3566-4A7F-913B-10B4B96F80D5Q37377923-0A453773-CE75-46D4-BC38-E91C26EBEE22Q37727650-F2485E47-5078-4C17-B5B3-B5F43FCD7591Q37781697-66D000CA-7630-4936-B009-0FA3A4C65402Q37940918-C766C26D-B128-40BC-9A5F-CE1399095CDDQ38163242-5F0E33AF-459D-48BD-BEB5-54B69A6080C3Q38291696-AD9A29CD-53BF-4676-AC0F-86BB7D03250DQ38294619-60A6E7E4-B54D-4BB1-8DDE-58CCC9624913Q38355000-9FE49D5D-151F-42DF-B05D-26696248F95FQ39024745-DFB1658A-199A-430D-9512-B8C11C08740CQ39473725-60BD13BD-1CE8-47F9-A4A6-2ABD15C3465DQ40037876-E8433187-AEAA-4EC7-B535-BCFD347412AEQ42499872-CA6B18DB-1955-4924-A969-03181C3D7756Q43042591-1D2EF266-C1B5-4D8B-8E7F-2C575D6E08F3Q45365788-D5468D0A-CDDD-480E-9A30-826FFA9C74A6Q50199678-90FA3DB6-0176-4246-9893-3DF36478F4BFQ51076481-30F9BFF4-F754-4209-8C53-7F5A327E071CQ55154176-52AF3436-3817-407D-9379-A05934BE4A44Q56656130-57998399-EA68-4A45-AE53-E683AAC2D3BAQ57492005-E67D7575-597E-4683-A89A-C6E7196569A0
P2860
Controlling complement resistance in cancer by using human monoclonal antibodies that neutralize complement-regulatory proteins CD55 and CD59.
description
2005 nî lūn-bûn
@nan
2005 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Controlling complement resista ...... latory proteins CD55 and CD59.
@ast
Controlling complement resista ...... latory proteins CD55 and CD59.
@en
type
label
Controlling complement resista ...... latory proteins CD55 and CD59.
@ast
Controlling complement resista ...... latory proteins CD55 and CD59.
@en
prefLabel
Controlling complement resista ...... latory proteins CD55 and CD59.
@ast
Controlling complement resista ...... latory proteins CD55 and CD59.
@en
P2093
P2860
P356
P1476
Controlling complement resista ...... latory proteins CD55 and CD59.
@en
P2093
Daniele Sblattero
Federica Ziller
Francesco Tedesco
Roberto Marzari
P2860
P304
P356
10.1002/EJI.200425920
P407
P577
2005-07-01T00:00:00Z